Stem cell advocates seek FDA path peptides won under MAHA
STAT reports lobbyists are modeling their deregulation campaign on the political embrace that gave unapproved peptide therapies new standing at the agency.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 5 04:30 ETSource: STAT
The wire
- 01STAT reports that stem cell treatment advocates are pressing the FDA for the same regulatory accommodation peptides received after being championed by Robert F. Kennedy Jr. and the MAHA movement.
- 02The piece frames peptides as the template case for how political pressure, not new clinical data, shifted FDA posture on a category clinicians and compounders depend on.
- 03Whether any formal FDA policy follows for stem cells is unsettled; the article describes advocacy and momentum rather than issued guidance or rulemaking.
From the source
Read at statnews.comSTAT+: Are stem cells the next peptides? These advocates think RFK Jr. could make it happen
Peptides gained legitimacy at the FDA after being embraced by MAHA. Advocates hope stem cell treatments will follow the same path.
